Liposome-encapsulated curcumin suppresses neuroblastoma growth through nuclear factor-kappa B inhibition

Surgery. 2012 May;151(5):736-44. doi: 10.1016/j.surg.2011.12.014. Epub 2012 Jan 28.

Abstract

Background: Nuclear factor-κB (NF-κB) has been implicated in tumor cell proliferation and survival and in tumor angiogenesis. We sought to evaluate the effects of curcumin, an inhibitor of NF-κB, on a xenograft model of disseminated neuroblastoma.

Methods: For in vitro studies, neuroblastoma cell lines NB1691, CHLA-20, and SK-N-AS were treated with various doses of liposomal curcumin. Disseminated neuroblastoma was established in vivo by tail vein injection of NB1691-luc cells into SCID mice, which were then treated with 50 mg/kg/day of liposomal curcumin 5 days/week intraperitoneally.

Results: Curcumin suppressed NF-κB activation and proliferation of all neuroblastoma cell lines in vitro. In vivo, curcumin treatment resulted in a significant decrease in disseminated tumor burden. Curcumin-treated tumors had decreased NF-κB activity and an associated significant decrease in tumor cell proliferation and an increase in tumor cell apoptosis, as well as a decrease in tumor vascular endothelial growth factor levels and microvessel density.

Conclusion: Liposomal curcumin suppressed neuroblastoma growth, with treated tumors showing a decrease in NF-κB activity. Our results suggest that liposomal curcumin may be a viable option for the treatment of neuroblastoma that works via inhibiting the NF-κB pathway.

Publication types

  • Evaluation Study
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Retracted Publication

MeSH terms

  • Animals
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Apoptosis / drug effects
  • Biomarkers, Tumor / antagonists & inhibitors*
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Curcumin / administration & dosage
  • Curcumin / pharmacology
  • Curcumin / therapeutic use*
  • Disease Models, Animal
  • Electrophoretic Mobility Shift Assay
  • Humans
  • Liposomes
  • Mice
  • Mice, SCID
  • NF-kappa B / antagonists & inhibitors*
  • Neovascularization, Pathologic
  • Neuroblastoma / drug therapy*
  • Neuroblastoma / metabolism
  • Real-Time Polymerase Chain Reaction
  • Treatment Outcome
  • Tumor Burden / drug effects

Substances

  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Liposomes
  • NF-kappa B
  • Curcumin